<DOC>
	<DOCNO>NCT01061736</DOCNO>
	<brief_summary>Primary Objectives : Part A ( dose range study ) : To demonstrate sarilumab ( SAR153191/REGN88 ) top methotrexate ( MTX ) effective reduction sign symptom rheumatoid arthritis 12 week . Part B ( pivotal study ) : To demonstrate sarilumab added MTX effective : - reduction sign symptom rheumatoid arthritis 24 week - inhibition progression structural damage 52 week - improvement physical function 16 week Secondary Objectives : Part B : To demonstrate sarilumab added MTX effective induction major clinical response 52 week To assess safety sarilumab add MTX To document pharmacokinetic profile sarilumab add MTX patient active rheumatoid arthritis inadequate responder MTX therapy .</brief_summary>
	<brief_title>Evaluation Sarilumab ( SAR153191/REGN88 ) Top Methotrexate Rheumatoid Arthritis Patients</brief_title>
	<detailed_description>The total study duration patient 16-22 week ( Part A ) 56-62 week ( Part B ) broken follow : - Screening : Up 4 week - Treatment : 12 week ( Part A ) 52 week ( Part B ) * - Follow-up : 6 week ( patient continue long-term extension study ) . '* ' Patients successfully complete treatment period offer opportunity enter long term extension study LTS11210 ( EXTEND ) .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<criteria>Inclusion criterion : Diagnosis rheumatoid arthritis â‰¥ 3 month duration Active disease define : least 8/68 tender joint 6/66 swollen joint , high sensitivity Creactive protein ( hsCRP ) &gt; 6 mg/l , continuous treatment MTX least 12 week prior baseline visit stable dose least 6 week prior screen visit Part B : Bone erosion base documented Xray prior first study drug intake , Cyclic Citrullinated Peptide ( CCP ) positive , Rheumatoid Factor ( RF ) positive Exclusion criterion : Age &lt; 18 year &gt; 75 year . Treatment diseasemodifying antirheumatic drug ( DMARDs ) MTX within 4 week 12 week prior screen ( depend DMARDs ) . Past history non response prior Tumor Necrosis Factor ( TNF ) biologic treatment . Any past current biologic agent treatment rheumatoid arthritis within 3 month . Use parenteral glucocorticoid intraarticular glucocorticoid within 4 week prior screen visit . Use oral glucocorticoid great 10mg/day equivalent/day , change dosage within 4 week prior baseline visit . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>